Management of Acute Kidney Injury in Non-Critically Ill Patients
In non-critically ill patients with AKI, focus on identifying and reversing the underlying cause, optimizing fluid status, immediately stopping all nephrotoxic medications, and ensuring nephrology involvement for patients requiring dialysis or with complex presentations. 1, 2
Diagnostic Approach
Define AKI using KDIGO criteria:
- Serum creatinine increase ≥0.3 mg/dL within 48 hours, OR
- Serum creatinine increase ≥1.5 times baseline within 7 days, OR
- Urine output <0.5 mL/kg/h for 6 hours 2
Stage the severity (Stage 1-3 based on creatinine rise and urine output) to guide intensity of monitoring and intervention 1, 2.
Classify the etiology into prerenal (volume depletion, poor perfusion), intrinsic renal (acute tubular necrosis, glomerulonephritis, interstitial nephritis), or postrenal (obstruction). This classification directly determines treatment 3, 4.
Essential initial workup:
- Review medication list for nephrotoxins (NSAIDs, aminoglycosides, ACE-I/ARBs, contrast agents)
- Assess volume status clinically (jugular venous pressure, mucous membranes, skin turgor, orthostatic vitals)
- Urinalysis with microscopy
- Fractional excretion of sodium (FENa <1% suggests prerenal)
- Renal ultrasound to exclude obstruction, particularly in older men 3
Immediate Management Priorities
1. Medication Review and Adjustment
Stop all nephrotoxic medications immediately including NSAIDs, aminoglycosides, and consider holding ACE-I/ARBs during the acute phase 1, 5. The timing of ACE-I/ARB reinitiation remains an area requiring clinical judgment based on context (heart failure, volume status) 1.
Adjust dosing of all renally-cleared medications based on current GFR 3.
2. Fluid Management
For prerenal AKI (hypovolemia): Administer intravenous fluid resuscitation. While the optimal fluid type remains debated, consider balanced crystalloid solutions over 0.9% saline given emerging concerns about hyperchloremic acidosis, though definitive evidence of harm from saline on kidney outcomes is still being investigated 1, 3.
For euvolemic/hypervolemic patients: Avoid aggressive fluid administration. Fluid overload detection and appropriate removal (diuretics or dialysis) should be prioritized, as positive fluid balance worsens outcomes 1.
Common pitfall: The audit data shows fluid administration remains suboptimal even when hypovolemia is recognized—clinicians must act on their assessment 5.
3. Address Underlying Causes
- Prerenal: Restore renal perfusion through volume resuscitation or treatment of heart failure/cirrhosis
- Intrinsic: Treat specific causes (stop offending drug for interstitial nephritis, immunosuppression for glomerulonephritis)
- Postrenal: Urgent urological intervention for obstruction (Foley catheter for bladder outlet obstruction, urology consult for ureteral obstruction)
4. Metabolic Management
Monitor and correct electrolyte abnormalities:
- Hyperkalemia (dietary restriction, potassium binders, dialysis if refractory)
- Metabolic acidosis (sodium bicarbonate may have a role, though evidence is evolving) 1
- Avoid magnesium-containing medications
When to Involve Nephrology
Immediate nephrology consultation for:
- AKI requiring dialysis
- Stage 3 AKI (creatinine ≥3x baseline or ≥4.0 mg/dL)
- Suspected intrinsic renal disease (glomerulonephritis, vasculitis)
- Unclear etiology despite initial workup
- Refractory electrolyte abnormalities
Critical evidence: Non-critically ill patients with dialysis-requiring AKI managed by nephrology teams (closed-staff organization) have significantly lower mortality (20% vs 52%) compared to general medical wards 6. This represents an independent mortality risk factor even after adjusting for severity and comorbidities.
Indications for Dialysis
Absolute indications:
- Refractory hyperkalemia
- Severe volume overload unresponsive to diuretics
- Uremic complications (encephalopathy, pericarditis, pleuritis)
- Severe metabolic acidosis
- Certain toxin removal 3, 4
Important consideration: Among non-critically ill patients requiring dialysis, 40% remain dialysis-dependent, with baseline CKD, previous AKI episodes, and parenchymal causes being significant risk factors 7.
Monitoring and Follow-up
During hospitalization:
- Daily serum creatinine and electrolytes
- Strict intake/output monitoring
- Daily weight
- Reassess volume status and medication list daily
Post-discharge care is critical but often neglected:
- All patients need kidney function monitoring within 3 months of AKI 8
- Patients with incomplete recovery need earlier follow-up (within 2-4 weeks)
- Check urinary albumin-to-creatinine ratio
- 76% of dialysis-independent survivors develop CKD by 3 months 7
- Optimize cardiovascular risk management and consider RAAS inhibitors and SGLT2 inhibitors for CKD prevention 8
Implementation Strategies
System-level interventions improve outcomes:
- Electronic AKI alerts significantly improve recognition 5, 9
- AKI care bundles increase likelihood of appropriate fluid assessment and nephrotoxin discontinuation 5
- Standardized referral pathways to nephrology 9
However, even with care bundles, compliance remains suboptimal (only 8.4% of patient-days met all audit measures in one study), indicating need for ongoing education and system reinforcement 5.
Key Pitfalls to Avoid
- Failing to recognize AKI early: Use electronic alerts and daily creatinine monitoring
- Continuing nephrotoxic medications: Review medication list daily
- Inadequate fluid resuscitation in prerenal AKI or excessive fluids in other contexts
- Delaying nephrology consultation in complex or severe cases—specialty involvement improves outcomes 6
- Lack of post-discharge follow-up: AKI survivors have high risk of CKD, recurrent AKI, and cardiovascular events 7, 8